Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies
Marina Ayres Pereira, Iok In Christine Chio
Genes (2019) Vol. 11, Iss. 1, pp. 6-6
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
Marcel Alexander Heinrich, Ahmed M. R. H. Mostafa, Jennifer P. Morton, et al.
Advanced Drug Delivery Reviews (2021) Vol. 174, pp. 265-293
Open Access | Times Cited: 85
Laminin‑332 mediates proliferation, apoptosis, invasion, migration and epithelial‑to‑mesenchymal transition in pancreatic ductal adenocarcinoma
Caiqun Huang, Jun Chen
Molecular Medicine Reports (2020) Vol. 23, Iss. 1, pp. 1-1
Open Access | Times Cited: 47
Recent advances in cancer-on-a-chip tissue models to dissect the tumour microenvironment
Kimberly Seaman, Yu Sun, Lidan You
Med-X (2023) Vol. 1, Iss. 1
Open Access | Times Cited: 11
HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B
Parmanand Malvi, Suresh Chava, Guoping Cai, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101285-101285
Open Access | Times Cited: 11
Focal pancreatic parenchymal atrophy could be a precursor of pancreatic cancer
Masataka Kikuyama, Jun Nakahodo, Kazuro Chiba, et al.
Pancreatology (2025)
Closed Access
Fast-Relaxing Hydrogels Promote Pancreatic Adenocarcinoma Cell Aggressiveness through Integrin β1 Signaling
Han Nguyen, Ngoc Ha Luong, Jacqueline Peil, et al.
Biomacromolecules (2025)
Closed Access
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Tarık Demir, Carolyn Moloney, Devalingam Mahalingam
Cancers (2025) Vol. 17, Iss. 5, pp. 715-715
Open Access
Targeting siRNA Nanoparticles with ApoB Peptide: Formulation, Biodistribution, and Bioactivity in Pancreatic Tumor-bearing Mice
Majd Agbaria, Doaa Jbara-Agbaria, Gershon Golomb
Journal of Drug Delivery Science and Technology (2025), pp. 106900-106900
Open Access
Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives
Prashant S. Kharkar
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 24, pp. 15279-15307
Closed Access | Times Cited: 32
TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer
Ying Tan, Xuanna Li, Zhenfeng Tian, et al.
Biochemical Pharmacology (2020) Vol. 189, pp. 114085-114085
Closed Access | Times Cited: 28
Organ-Chip Models: Opportunities for Precision Medicine in Pancreatic Cancer
Muhammad R. Haque, Trevor Rempert, Taslim A. Al-Hilal, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4487-4487
Open Access | Times Cited: 27
The Liver Pre-Metastatic Niche in Pancreatic Cancer: A Potential Opportunity for Intervention
Peter Gumberger, Bergþór Björnsson, Per Sandström, et al.
Cancers (2022) Vol. 14, Iss. 12, pp. 3028-3028
Open Access | Times Cited: 18
Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting
Annalisa Pappalardo, Emilio Francesco Giunta, Giuseppe Tirino, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 21
ATG7 is a haploinsufficient repressor of tumor progression and promoter of metastasis
Jaclyn S. Long, Elżbieta Kania, David G. McEwan, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 28
Open Access | Times Cited: 15
Laminarin Attenuates ROS-Mediated Cell Migration and Invasiveness through Mitochondrial Dysfunction in Pancreatic Cancer Cells
Woonghee Lee, Gwonhwa Song, Hyocheol Bae
Antioxidants (2022) Vol. 11, Iss. 9, pp. 1714-1714
Open Access | Times Cited: 13
Screening of MMP-2 Inhibiting Phytoconstituents for the Development of Newer Pancreatic Cancer Treatment Modalities
Loganayaki Periyasamy, Bharathi Murugantham, Sundaraj Rajamanikandan, et al.
Protein and Peptide Letters (2023) Vol. 30, Iss. 4, pp. 304-313
Closed Access | Times Cited: 7
Tumor Microenvironment Modulates Invadopodia Activity of Non-Selected and Acid-Selected Pancreatic Cancer Cells and Its Sensitivity to Gemcitabine and C18-Gemcitabine
Tiago M. A. Carvalho, Madelaine Magalì Audero, Maria Raffaella Greco, et al.
Cells (2024) Vol. 13, Iss. 9, pp. 730-730
Open Access | Times Cited: 2
Robust and consistent biomarker candidates identification by a machine learning approach applied to pancreatic ductal adenocarcinoma metastasis
Tanakamol Mahawan, Teifion Luckett, Ainhoa Mielgo Iza, et al.
BMC Medical Informatics and Decision Making (2024) Vol. 24, Iss. S4
Open Access | Times Cited: 2
Neutrophils as promising therapeutic targets in pancreatic cancer liver metastasis
Minjie Guo, Wanying Sheng, Yuan Xiao, et al.
International Immunopharmacology (2024) Vol. 140, pp. 112888-112888
Closed Access | Times Cited: 2
WNT5A is a putative epi‐driver of prostate cancer metastasis to the bone
E. J. Wilkinson, Kelsie Raspin, RC Malley, et al.
Cancer Medicine (2024) Vol. 13, Iss. 16
Open Access | Times Cited: 2
Errα Promotes Pancreatic Cancer Progression by Enhancing the Transcription of PAI1 and Activating the MEK/ERK Pathway
Shuli Liu, Ping Dong, Xiaofeng Wang, et al.
HPB (2022) Vol. 24, pp. S259-S260
Open Access | Times Cited: 11
Clinicopathological Features, Prognostic Factors and Survival in Patients With Pancreatic Cancer Bone Metastasis
Ying Ren, Shicheng Wang, Bo Wu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11
Insight of pancreatic cancer: recommendations for improving its therapeutic efficacy in the next decade
Zhi-Hang Xu, Wenquan Wang, Wenhui Lou, et al.
Journal of Pancreatology (2022) Vol. 5, Iss. 2, pp. 58-68
Open Access | Times Cited: 11
Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer
Shilei Liu, Haibin Liang, Ziyi Yang, et al.
International Journal of Medical Sciences (2022) Vol. 19, Iss. 2, pp. 286-298
Open Access | Times Cited: 10
NLRX1 functions as a tumor suppressor in Pan02 pancreatic cancer cells
Margaret A. Nagai-Singer, Holly A. Morrison, Mackenzie K. Woolls, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top